MOTS-C

Mitochondria-derived peptide with preclinical metabolic/exercise-related findings; limited established human efficacy evidence.

goal:endurancegoal:aerobicgoal:longevity-metabolic-cardiovasculargoal:metabolicconstraint:not-drug-test-safeevidence:very-lowstudy:mechanistic-animalpop:other-unclearform:other

Dosing model

FLATFixed dose (no body-weight scaling).

Min dose

—

Max dose

—

Rounding

—

Buy this ingredient ← Back

Stacks containing MOTS-C

Public community stacks that include this ingredient.

Explore all stacks →

endurancefatiguereadiness

Research-only: Mito / Fatigue / Readiness (SS-31 + MOTS-C)

by@athlete

Mitochondria-oriented peptide grouping. SS-31 has clinical trials in specific mitochondrial diseases; MOTS-C is mostly preclinical.

SS-31 (Elamipretide)

1mg

MOTS-C

1mg

New

View

Evidence

3 records

Running performance under metabolic stress

Mice on high-fat diet (preclinical) • Animal study

Low

In mice, MOTS-c treatment improved treadmill running performance under diet-induced metabolic stress and showed metabolic regulatory effects.

Dose: — • Duration: Preclinical protocol (see paper)

Citation: Reynolds et al., Nat Commun (2021) — exercise-induced MOTS-c biology and performance in mice

Clinical translation status

Humans (clinical development commentary) • Review / perspective

Low

Reviews note that clinical trials to test therapeutic MOTS-c potential are limited/ongoing; overall human efficacy evidence remains early. Blood MOTS-c levels are reported lower in type 2 diabetes and obesity, but therapeutic dosing in humans has not been validated.

Dose: —

Citation: Lee et al., Diabetes Metab J (2023) — MOTS-c, diabetes, and related clinical perspective

Exercise/metabolic signaling (summary)

Mostly preclinical • Review

Very low

Reviews propose metabolic and stress-response roles primarily based on preclinical evidence; no effective method of applying MOTS-c in the clinic has been established as of 2024-2025.

Dose: —

Citation: Ming et al., Front Endocrinol (2023) — MOTS-c: A promising mitochondrial-derived peptide for therapeutic exploitation

Forms

Other

Research material (vendor listing)